MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve MyelofibrosisJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|Journal of Clinical Oncology|2023Cited by 89
Phase III MANIFEST-2: Pelabresib + Ruxolitinib vs Placebo + Ruxolitinib in JAK Inhibitor Treatment-Naive MyelofibrosisClaire Harrison, John Mascarenhas, Adam J. Mead et al.|Future Oncology|2022Cited by 40
MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis PatientsJohn Mascarenhas, Srđan Verstovšek, Claire Harrison et al.|Blood|2020Cited by 21
MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST StudyJohn Mascarenhas, Vikas Gupta, Marina Kremyanskaya et al.|Clinical Lymphoma Myeloma & Leukemia|2022Cited by 13
Results from phase 1 of the MANIFEST clinical trial to evaluate the safety and tolerability of pelabresib in patients with myeloid malignanciesEytan M. Stein, James K. Mangan, Amir T. Fathi et al.|Leukemia & lymphoma/Leukemia and lymphoma|2024Cited by 13